Voting while God is watching does having churches as polling stations sway the ballot? – Huron Daily Tribune

Eds: This story was supplied by The Conversation for AP customers. The Associated Press does not guarantee the content.

Jordan LaBouff, University of Maine

(THE CONVERSATION) Houses of worship may be busier than usual come Election Day as Americans head to the polls rather than the pews.

A 2010 census of religious congregations identified nearly 350,000 churches, mosques, temples and other religious establishments attended by more than 150 million Americans, primarily for spiritual needs and social relationships.

But during elections, such places double as centers of civic life serving as community polling places. In some electoral districts, houses of worship make up a significant number of all voting places, raising important issues about whether voting in a place of worship influences how people cast their ballots.

Church and state

Voting in religious spaces is nothing new.

Americans have long been casting their ballots in the same place where they or their neighbors worship. In early America, the town meeting house often served both religious and secular functions with the same space housing prayer meetings, schooling and town business.

Although the separation of church and state has largely moved the practice of religious and secular life into separate spheres, churches have continued to house voting booths.

As urban population densities have grown more than 500% from 1910 to 2010 election boards have been asked to identify polling sites that are large and empty enough to accommodate voters. They also need to be accessible and rent-free. Since government buildings can rarely accommodate these needs indeed, less than 1% of polling sites in 2018 were specifically election offices religious leaders have often offered their buildings as polling sites as a public service.

Although no national data on religious spaces as polling places exists, this arrangement appears to be very common.

For example, 22% of polling sites for the 2020 general election in Minneapolis are houses of worship. In St. Louis, 27% of precincts vote in religious spaces and, in one ward, all eight of the polling places are churches.

Priming voters

As a scholar who studies how social situations can influence attitudes, I believe where someone votes can subtly but significantly affect how they vote.

Social scientists have long understood that physical and social context shapes the way people think, feel and behave. Without even realizing it, most of us are likely to speak more quietly when talking about the possibility of visiting a library than when discussing plans to dine at an exclusive restaurant.

Each physical setting offers cues that, at least temporarily, prompt people to think and behave in ways consistent with stereotypes about that space. Scholars call this a priming effect.

Sometimes this happens consciously as people realize that they are influenced by the situation. For example, you might feel serious and reverent while visiting a war memorial. Much of the time, however, people arent aware of the subtle priming influences of everyday spaces.

These unconscious influences can be powerful.

For example, people in a business-themed room with briefcases and boardroom tables tended to act more competitive and self-interested in decisions than those making the same decisions in a classroom, researchers found.

Similarly, on average, people who could see a sports drink rather than a bottle of water ran longer on a treadmill. And those hearing French music over supermarket loudspeakers were more likely to buy French wine than when German music was playing.

[Expertise in your inbox. Sign up for The Conversations newsletter and get expert takes on todays news, every day.]

Ballot bias

These effects extend to the polling booth.

In Arizonas 2000 general election, citizens voting in schools were more likely to support a state sales tax increase to fund education than citizens with similar social and political characteristics who cast ballots elsewhere.

In a related laboratory study, voters shown images of a school encouraged support for education-oriented taxation, whereas images of a church reduced support for stem-cell research.

In 2012, my colleagues and I asked approximately 100 participants from more than 20 different countries to answer questions about their political attitudes and feelings toward various minority groups while standing in front of a cathedral or City Hall in Maastricht, the Netherlands.

Regardless of their own religious identity or beliefs, respondents who could see the church supported more conservative approaches to issues such as immigration, taxes, drug policies, warfare and abortion than those who could see City Hall. They were also more prejudiced toward minorities such as gay men and immigrants especially those of Arab descent.

Our recent analysis of 2016 election data from Virginia reveals similar tendencies. Controlling for population, county-level religiosity and other factors, citizens casting their ballots in churches were significantly more likely to vote for Republican candidates than their nearly identical neighbors who were voting in secular venues.

This effect was strongest for counties with the highest proportion of religious people. That is, when Christians vote in churches, they seem to be even more likely to vote for conservative candidates than when they vote outside of churches.

Further, which houses of worship are selected may invite more bias into the polling booth. When a single mosque was included as a polling site among more than 50 churches in Palm Beach County, Florida, in 2016, the countys election board received complaints and threats of violence until they removed the mosque as a polling site.

Meanwhile, Christian churches are common polling sites even in communities that are not themselves predominantly Christian.

As a result, some citizens who may feel stigmatized and threatened by religious institutions are expected to visit them to vote.

Small influence but tight margins

Although some non-Christian citizens have complained that voting in churches violates their rights, courts have consistently ruled that the availability of alternatives such as absentee voting means that having places of religion serve as polling stations does not represent a violation of the First Amendment of the Constitution, which guarantees the freedom of religion.

In other words, where you are can influence who you are, even when you dont notice it. Although the influences of physical spaces are small and people are more likely to be influenced by these kinds of peripheral cues when they dont already have strong opinions on a topic, elections can be decided by fractions of a percent especially in consequential local races where people may enter the polling booth undecided, and thus be more susceptible to the influences of the space theyre in.

The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts. The Conversation is wholly responsible for the content.

Read this article:
Voting while God is watching does having churches as polling stations sway the ballot? - Huron Daily Tribune

Synthetic Stem Cells Market Research: Aim To Achieve The Pinnacle In Qualitative Industry Research And Business Intelligence – The Daily Chronicle

The report titled Synthetic Stem Cells Marketoffers a primary impression of the Synthetic Stem Cells industry covering different productScope, Characterizations, Classifications, Objectives, and Participantsin the industry chain structure. Synthetic Stem Cells Market (6 Forces Forecast 2020-2026) research report offers in-intensity insight of the Synthetic Stem Cells industry masking all vital parameters along with Marketing Channel, Direct Marketing, Indirect Marketing,Brand Strategy, Pricing Strategy,Market Positioning, Target Client, and Distributors/Traders List.

Synthetic Stem Cells market report profiles major topmost manufactures operating (North Carolina State University, Zhengzhou University) in terms of analyses various attributes such asCompany Profile, Product Specifications, Revenue, Gross, Gross Margin, Cost, Capacity, CAGR, Production Valueand contact information.

Get Free Sample PDF (including full TOC, Tables and Figures)of Synthetic Stem Cells [emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2395700

Synopsis of Synthetic Stem Cells Market:Synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Cardiovascular Diseases Neurological Disorders Other Diseases

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Synthetic Stem Cells market for each application, including-

Cancers Wounds and Injuries Musculoskeletal Disorders Blood disorders

Synthetic Stem Cells Market: Regional Analysis Includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2395700

The Synthetic Stem Cells Market Report Helps Answer the Following Questions:

What is the current size of the overall Synthetic Stem Cells market? How much will this market be worth from 2020 to 2026?

What are the market shares of the leading segments of the Synthetic Stem Cells market in 2020?

What are the main segments within the overall Synthetic Stem Cells market? How much will each of these segments be worth for the period 2015 to 2026?

What are the main drivers and restraints in the Synthetic Stem Cells market?

What are the leading business manufactures? What are their revenue potentials to 2026?

What are the major deals happenings in the manufactures Synthetic Stem Cells market?

Who are the leading manufactures and what are their activities, revenue, recent developments and prospects?

What are some of the most prominent Synthetic Stem Cells market currently in development? What are their activities, platform technology and recent developments?

Contact:

ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

See the original post here:
Synthetic Stem Cells Market Research: Aim To Achieve The Pinnacle In Qualitative Industry Research And Business Intelligence - The Daily Chronicle

Cell Line Development Market Report Analysis with Industry Share Insights Shared in Detailed Report – The Daily Chronicle

Cell line development is an important technology in life sciences. Stable cell lines are used for various applications including monoclonal antibody and recombinant protein productions, gene functional studies, and drug screening. Manual screening method is a traditional method used for cell line development. This method is tend to be disadvantageous as it is labor-intensive and time-consuming. Automation in tools used for cell line development is likely to replace manual methods of cell line development.

Cell line development and culturing is being rapidly adopted in areas of biological drug developments for various chronic diseases, regenerative medicines such as stem cells & cell-based therapies, recombinant protein, and other cellular entities for pharmaceuticals, diagnostics, and various other industries

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75773

Global Cell Line Development Market Witness Most Promising Rise in Demand:

Rise in focus on research & development, owing to increase in prevalence of cancer and other chronic diseases is anticipated to drive the market. Several institutes, such as Cancer Research Institute, National Cancer Institute, Advanced Centre for Treatment, Research and Education in Cancer (Cancer Research Centre [ICRC]), and NCI Community Oncology Research Program (NCORP), are engaged in research & development for cancer diagnosis and treatment. Hence, the initiative of government and non-government organizations is likely boost the growth of the market.

Advances in bioinformatics and recombinant technologies have led to development of new cell lines for synthesis or production of essential peptides, enzymes, saccharides, and other molecules which are being used in pharmaceuticals and various other industries.

Request for Analysis of COVID19 Impact on Cell Line Development Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75773

The global cell line development market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Key players engaged in adopting new strategies are likely to drive the global cell line development market. Key players are developing new, cost-effective biologic products. This is anticipated to augment the market.

Key Players of Cell Line Development Market Report:

This report profiles major players in the global Cell Line Development market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Merck KGaA, Selexis SA, Lonza, ATCC, Solentim Ltd. Sphere Fluidics Limited, WuXi Biologics, Thermo Fisher Scientific, GE Healthcare, Aragen Bioscience Contract Manufacturer, Sartorius AG

Buy Cell Line Development Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=75773&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Follow this link:
Cell Line Development Market Report Analysis with Industry Share Insights Shared in Detailed Report - The Daily Chronicle

Global Vaccine, Insulin and Stem Cell Market Research Report Profitable Segments, Current and Future Industry Analysis till 2026 – The Daily Chronicle

The progressive growth trail of Vaccine, Insulin and Stem Cell Market covering global, regional, country-level Analysis from 2015-2027 is studied in this report. The first 2 quarters of 2020 have resulted in disruptions of different industry segments like Vaccine, Insulin and Stem Cell supply chain, revenue, sales, demand, and gross margin. The industry with an influx of opportunities across different Vaccine, Insulin and Stem Cell types and applications is studied in this report. Although some industry segments have temporarily scaled back, the industry forecast reflects good opportunities ahead. All recent developments, changes in business plans and policies, import-export statistics, and mergers & acquisitions are specified. The post-pandemic crisis, Vaccine, Insulin and Stem Cell risk mitigation factors, evolving through a pandemic, and profitable Vaccine, Insulin and Stem Cell factors are studied.

Primarily, the Global Vaccine, Insulin and Stem Cell Research Report evaluates the historic market performance from 2015-2019 with the base year as 2019 and estimated year as 2020. All our reports are updated considering the pandemic impact on various Vaccine, Insulin and Stem Cell Industry verticals and emerging segments. The projected years are 2020-2027. The industry dynamics, market performance, assessment of Vaccine, Insulin and Stem Cell demand, supply chain, and manufacturing scenarios are comprehensively analyzed.

Request FREE sample copy of Vaccine, Insulin and Stem Cell Industry Assessment Research Report 2015-2027 here:https://www.reportscheck.com/shop/global-vaccine-insulin-and-stem-cell-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/#sample-request

Note:Our domain-specific expert analyst team is keenly monitoring COVID-19 impact on Vaccine, Insulin and Stem Cell Industry segments and sub-segments for better market understanding. The latest updated 2020 report edition offers COVID-19 impact on various industry segments with an economic slowdown, product demand fluctuations, and revenue accumulation.

Browse Complete Table of Contents (Or make a custom request/send any query):https://www.reportscheck.com/shop/global-vaccine-insulin-and-stem-cell-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/#table-of-contents

Market segmentation is based on top players, regions, countries, types, and applications. The company profiles of top market players, raw material suppliers, equipment suppliers, end-users, and distributors analysis.

Complete company profiles, competitive Vaccine, Insulin and Stem Cell Industry assessment, gross margin sales of top companies, revenue, volume analysis, and market size estimation. The consumption rate, import-export, future strategies and business plans, technological developments, and complete historic industry performance is specified.

The SWOT analysis, Porter Five Forces analysis, and PESTLE analysis is conducted to identify market strengths, opportunities, risk factors.

All the quantitative and qualitative Vaccine, Insulin and Stem Cell information in terms of market numbers and industrys 360-degree overview is presented.

The report begins with an industry overview, definition, development, current situation, and Vaccine, Insulin and Stem Cell aspects of the pandemic. The market status and revenue in (Million USD) is offered. The product features, pricing structure, Vaccine, Insulin and Stem Cell marketing, and sales channel analysis.

The investment opportunity, channel, feasibility check, regional and country-level investment is provided. The upstream raw material providers and downstream buyers are provided. The sales revenue, sales volume, price, cost, gross margin is provided.

The report covers Vaccine, Insulin and Stem Cell business insights, market size, share, CAGR, key vendors, and competitive view. The market-centric research methodology comprising of Vaccine, Insulin and Stem Cell quantitative and qualitative inputs are offered. The SWOT analysis, growth trends, regional analysis is provided.

Paid primary interview with key opinion leaders of Vaccine, Insulin and Stem Cell Industry as well as paid secondary data sources and reliable data is used. Customization is exclusively available with us based on the clients stated scenario.

Vaccine, Insulin and Stem Cell Forecast based on volume, value, revenue, and sales is offered for our clients to make a strategic and profitable move.

Macroeconomic factors, top-down and bottom-up research approach are used to derive Vaccine, Insulin and Stem Cell data points.

Data triangulation method is followed to validate the market numbers and provide accurate analysis.

The strength, opportunities, key Vaccine, Insulin and Stem Cell driving forces, sales margin, and cost structure evaluation is conducted. The top player's analysis is an important factor that will help in understanding the industry competition.

Strategic Vaccine, Insulin and Stem Cell Industry evaluation, growth analysis, developmental trends, understanding of changing industry dynamics are key highlights of our report. The decision-marking aspects like Vaccine, Insulin and Stem Cell market entry strategies, market sizing, technology trends, and innovations are offered.

To know more about us browse our latest reports released:https://www.reportscheck.com/shop/global-vaccine-insulin-and-stem-cell-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/

Contact Us:

Olivia Martin

Marketing Manager

Email:[emailprotected]

Website:www.reportscheck.com

View original post here:
Global Vaccine, Insulin and Stem Cell Market Research Report Profitable Segments, Current and Future Industry Analysis till 2026 - The Daily Chronicle

Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing – Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as the Companys Senior Vice President of Intellectual Property and Licensing. Mr. Gallagher has extensive experience in the area of biotechnology intellectual property (IP) law, business development, and licensing transactions with industry and academic institutions.

Mr. Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the Companys overall success and value creation. A seasoned biotech executive, he will provide significant support as we execute on broadening our research and development programs, explore opportunities for partnerships on our existing programs, and opportunistically acquire new technologies to further expand our pipeline, said Rodney Varner, President and Chief Executive Officer of Genprex.

Mr. Gallagher has more than 20 years of experience as an intellectual property attorney. Prior to joining Genprex, he served as Principal at the Fenagh Group, an IP and licensing consultancy providing clients in the healthcare sector guidance on all aspects of patent and trademark portfolio management, intellectual property due diligence, freedom-to-operate analysis and related transactional work. He has also served as Senior Vice President of Intellectual Property and Licensing at Kadmon Corporation, LLC, a biopharmaceutical company based in Manhattan. Prior to joining Kadmon, he served as in-house IP counsel at Neostem Inc. (now Caladrius Biosciences, Inc.), a company focused on stem cell biology. Previously, he held several positions at ImClone Systems Incorporated, most recently as Vice President of Intellectual Property and Licensing. While at ImClone, he was responsible for all aspects of intellectual property and led the IP function in multiple due diligence undertakings by major pharmaceutical companies, which resulted in a $2 billion strategic investment, the highest-valued biotech deal ever at the time, and the eventual sale of the company to Eli Lilly and Company for $6.5 billion.

Mr. Gallagher is experienced in both patent prosecution and litigation, as well as intellectual property issues relating to business development and licensing matters. His patent litigation experience includes European litigation and opposition proceedings. In addition to a law degree, Mr. Gallagher holds a Masters degree in molecular biology. Before becoming an attorney, Mr. Gallagher worked as a molecular biologist in France, Spain and the United States.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

See original here:
Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing - Business Wire

Changing STEM Representation Trends Through the Philadelphia AMP Alliance – DrexelNow – Drexel Now

Jazmean Williams, a 2020 graduate with a BS in biomedical engineering, in the lab during her six-month research co-op in Wellington, New Zealand funded partially by Drexel-LSAMP.

When Stephen Cox started as an undergraduate student at Drexel University (then called the Drexel Institute of Technology) in 1969, it was sparsely populated with minority students like him, he says.

Then, after receiving his BS in physics and atmospheric science in 1974 and his MS in biophysics and biomedical engineering (both from Drexel) in 1976, Cox left Drexel and jumped into an industry career with positions at General Electric and Boeing. There, he saw a similar trend very few people of color were operating alongside him in these scientific positions and venues.

So in the early 90s, Cox started working to reverse this trend, and he had help. The National Science Foundation (NSF) wanted to establish multi-year, multi-million-dollar grants to support institutions and programming proven to increase the number of underrepresented students moving into STEM-related paths of study and, ultimately, careers.

In 1994, this funding and Coxs work helped found the Greater Philadelphia Region Alliance for Minority Participation (Philadelphia AMP), which is part of the national, NSF-founded Louis Stokes Alliances for Minority Participation (LSAMP) program. Philadelphia AMP brought together nine higher-education institutions to work and share resources toward a common goal to double the number of minority students receiving degrees in STEM disciplines over the next five years as this NSF-funded alliance model had already proven successful in doing so in additional areas of the country.

Stephen Cox (BS '74 MS '76) is co-principal investigator and project director of Philadelphia AMP.

And in that five-year time frame, Philadelphia AMP had more than achieved the goal, and Cox had also been invited to headquarter the alliance at his alma mater. He is now co-principal investigator and project director of Philadelphia AMP, leading the alliance alongside Nina Henderson Provost Paul Jensen, PhD, and Aroutis Foster, PhD, an associate dean of Drexels School of Education.

Because I knew of the impact of cooperative education, I thought that Drexel would be a good site to create the leadership of the initiative, he said.

Now, the 27-year-old Philadelphia AMP Alliance continues to thrive at host institution Drexel and across partner institutions, including the University of Pennsylvania, Temple University, Community College of Philadelphia, Cheyney University of Pennsylvania, Lincoln University, the University of Delaware, Delaware State University and Rowan University. The LSAMP model has also taken hold in all areas of the country, from Puerto Rico to Hawaii.

Each university in the Philadelphia Alliance supports its own programming, activities, research opportunities, academic coaching, mentorship and funding, and the institutions also support each other, all in an effort to sustain what is now the annual graduation of well over 1,000 minority students into STEM graduate and PhD programs or careers. This is compared to the just 200 graduating with STEM degrees back before the alliance began.

As an alliance, we've been very successful in capturing the funding, but also providing the opportunities for students to succeed, who prior to this were not really looked at as a necessary outcome, Cox said. You know, it's easy to talk about being diverse, but the reality of diversity is how you produce a product and we've been able to do that successfully over a 26-year period, so much so that this year NSF has awarded us again a $3.2 million grant to continue this work from now through 2025.

The continued work of Philadelphia AMP is both important and complex, and critical in current turbulent times, Cox said.

We see right now, the country is in turmoil. Issues of race and ethnicity and gender are all things that are still issues 25, 30 years later, he added. That has not gone away in America.

But despite all this complexity, how Drexel students get involved with LSAMP on an individual level is often quite simple.

For Jazmean Williams, a 2020 graduate with a BS in biomedical engineering, it started with a friend encouraging her to come to an LSAMP meeting while she was on campus summer term of her first year participating in the STAR Scholars program.

Just hearing what some of the current students in the program were doing and how LSAMP had basically bolstered their research rsum and the different outreach programs that they were able to do, that just made me so excited, Williams remembered. So I was like, OK, I'm going to join and I'm going to be involved, and I've been involved ever since.

From that moment on, LSAMP became a very big part of Williams Drexel experience. Without it, she said many of the research opportunities she was able to do in undergrad wouldnt have been possible, including the six-month research co-op in New Zealand she completed last year, and through which she solidified her goal of doing stem cell research as a career.

Jazmean Williams enjoying some down time while on an LSAMP-funded research co-op in New Zealand.

Without LSAMP, I would have never been able to leave the ground, Williams said. [The program] was able to help pay for my plane ticket and also provided resources for finding housing.

Because of that experience, I feel like it made my rsum a lot more attractive. Its a great talking point, too. I'm able to just talk about the experience of living in a new country on my own and being involved within a new culture, she continued. It shows not only your flexibility, but your ability to adapt and ability to problem solve. So, yeah, it was just an awesome experience.

For Julian Rath and Salamata Bah, it started with an email from Drexel-LSAMP Director Marisol Rodriguez Mergenthal, which arrived in their inbox at the right time, offering the right opportunity. Rath was having trouble back in March securing his first co-op opportunity due to complications caused by the pandemic. Then he found out that through LSAMP, he could take an online scientific computing course taught by scientists of the Brookhaven National Laboratory that was bound to help give him a leg up in his area of career interest, nuclear science. Better yet, he could get paid to take the course.

There were literally no aspects of the opportunity that I could have ever considered turning down, Rath, a pre-junior majoring in chemistry, said. With the career that I'm planning on going into, I need as much experience and credibility as I can get. Taking a class with Brookhaven National Laboratory on how to actually use the programs utilized in the field should help me greatly in the future.

Funded by a part-time stipend from LSAMP, Rath went on to complete a co-op position with the Peace Innovation Institute arranged by Joseph Hughes, PhD, and other College of Engineering faculty.

Bah, now a second-year computer science major, got involved with LSAMP during her first year when she saw an email about a research project in partnership with Cheyney University. LSAMP students from both institutions worked with faculty on annotating videos and collecting data centered around machine learning. Bah even had the opportunity to design the front end of an application the team wanted to create for the research.

Salamata Bah, a second-year computer science major involved with Drexel-LSAMP.

Bah said this experience helped her be accepted and solidify a project for the STAR Scholars program this summer.

I chose to do something related to machine learning because I found it so interesting, she said.

Because of how much LSAMP helped shape their time at Drexel, all of these participants would encourage other eligible students to keep an eye out for emails about programming and get involved.

I wouldn't be doing half the things that I've been doing over the past six months if I just never got the email and I never signed up for it, Rath said. It's only done good things for me, basically. Its an opportunity just sitting there

You never know which one of them will help you in your career or just build the network that will help you in the future, Bah added.

Williams specifically encouraged eligible students to get involved early on in their Drexel career like she did, whether theyre students who hit the ground running or take more time to adjust.

It's really great to have someone who's like a cheerleader, who's willing to cheer you on and make sure that you're getting the resources that you need, getting involved in the things that you need to be involved in, and also just providing mental health advice and academic advice, she said. Even if you're not a student who's ready to just take on the world right once you step on the campus, it's good to have someone who's willing to guide you through that process and to also have other students and other upperclassmen who've been where you've been and who can also guide you through that process as well.

Through the years, Cox has enjoyed hearing from students how much the LSAMP program at their institution or the Philadelphia AMP Alliance as a whole benefitted their personal growth and development.

Many of them attribute their success in their life now, many of them have families and children that it had to do with working with me, because I told them that they could do anything they wanted to do if they really invested themselves in believing that they could do it, he said. Many times, while I could say that I was the catalyst for their success, the reality is they were the raw material that just needed some encouragement.

Cox will be taking the Philadelphia AMPs Phase VI grant period, which will carry the alliance through 2025 and 30 years of existence, to start grooming a predecessor to take over his role and continue with this important work.

The reality is I could probably do this forever because I really enjoy what I do, but I will be 72 in October of this year, he said. In order to ensure the same kind of energy and excitement about this continues, I need to groom some other people.

All in all, he was happy to play a part in reversing the trends he saw as a student 50 years ago, and help students not unlike himself over the past 25 years find success, motivation and community.

At one of our graduation sequences, as the students were walking across stage, I overheard [the late Drexel University President Constantine Papadakis] say, These are Steve Coxs kids, he remembered. For me, that kind of summed it up, because there are so many students that I invested my knowledge, my background in industry, my technical capacity and my belief that all students can learn, particularly underrepresented students, if they are given the opportunity.

To find out more about Drexel-LSAMP participation and programming, please contact the Director Marisol Rodriguez Mergenthal at mr444@drexel.edu.

Read more here:
Changing STEM Representation Trends Through the Philadelphia AMP Alliance - DrexelNow - Drexel Now

Shared protein fingerprint could simplify treatment of common inherited heart disease – University of Wisconsin-Madison

Hypertrophic cardiomyopathy is the most common inherited heart disease, marked by an abnormally thickened heart muscle that can obstruct blood flow and lead to sudden death in young adults.

A dizzying array of over 1,400 genetic mutations can lead to the disease, puzzling doctors on how to treat so many unique varieties. But in new research, University of WisconsinMadison scientists discovered that many different genetic mutations result in surprisingly similar changes to heart muscle proteins in patients with the most severe manifestations of hypertrophic cardiomyopathy. This shared protein fingerprint suggests that shared treatments could treat the disease.

This could be good news for doctors treating obstructive hypertrophic cardiomyopathy patients, because our data suggest theres a convergent pathway in these patients, allowing development of treatments that generally target patients with severe obstruction from their cardiomyopathy instead of targeting a patients individual genetic mutations, says Ying Ge, a professor of cell and regenerative biology and chemistry at UWMadison who headed the new study.

Ying Ge

Ge and an international collaboration of researchers published their findings the week of Sept. 21 in the Proceedings of the National Academy of Sciences. UWMadison graduate students Trisha Tucholski and Wenxuan Cai led the work, which analyzed in detail the protein signatures of diseased and normal hearts using advanced protein-measurement technology.

The team collected samples of diseased heart tissue from 16 patients who underwent corrective surgery to fix impaired blood flow in their hearts. Hypertrophic cardiomyopathy in eight of these patients was due to eight distinct mutations across two genes; for the other eight patients, the disease-causing mutations were unknown. Proteins from the diseased heart samples were compared to those from healthy donor hearts.

Despite the variation in underlying genetic mutations, Ges team discovered a general pattern in hearts from patients with the disease. For example, many key muscle proteins from diseased hearts had fewer molecular tags known as phosphates. While the exact consequence of having fewer phosphates is unknown, its likely that these altered proteins contribute to a general state of dysregulation in the heart, leading to the thickened muscle characteristic of the disease.

The findings reinforce that genetic mutations arent always enough to explain diseases, says Ge. The proteins those genes encode have the ultimate impact on health, and the bodys proteins can be altered in subtle but consequential ways during disease.

When we first performed these experiments, this similarity at the protein level was quite surprising to us because it is generally expected that different mutations could lead to different changes in the proteins, says Ge. But in reality, these results make sense, because when the patients with this disease present to the hospital for surgery, their hearts exhibit similar dysfunction.

The results are still preliminary. Ges group wants to expand to study hundreds of additional patients with a wide array of underlying hypertrophic cardiomyopathy mutations to see if the similar protein fingerprint trend holds. They also plan to study heart stem cells with disease-causing mutations in an effort to study early stages of the disease, which isnt possible with human patients.

But with additional research, this kind of in-depth analysis of protein fingerprints could guide future treatments.

This data opens the door with evidence showing that protein-level changes might be a better reflection of the patients disease than their genes, and if we can examine patients samples at the protein level, that could help us provide precision-medicine treatments, says Ge.

This work was supported in part by the National Institutes of Health (grants R01 HL096971, R01 GM117058, GM125085, HL109810, S10 OD018475, T32 GM008505, T32 GM008688, R01 HL129798, U01 HL134764, and R01 HL139883) and the National Science Foundation (grant EEC-1648035).

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Follow this link:
Shared protein fingerprint could simplify treatment of common inherited heart disease - University of Wisconsin-Madison

COVID is shifting the conversation about the medical application of CBD – Open Access Government

COVID-19 has spread around the planet, sending billions of people into lockdown as health services struggle to cope. The statistics are startling global cases stand at 23,139,628 and with a total death toll of 801,795 and new daily cases rising (John Hopkins University data 23 Aug 2020), the outbreak has thrown an unprecedented challenge to the world and its citizens. So far, there is no approved treatment or vaccine.

While researchers around the world continue to explore different ways in combating COVID-19, some are looking into how cannabis derived CBD can offer benefits for those suffering from severe forms of this infection.

One recent study from the Dental College of Georgia and Medical College of Georgiashowed high CBD formulations could be effective in the treatment of acute respiratory distress syndrome, or ARDS. The condition, also known as a cytokine storm, has been seen in serious cases of coronavirus, and even affects patients with other viruses or autoimmune diseases. With ARDS, the patients own hyperactive autoimmune system inundates organs with cytokines, resulting in dangerous inflammation. This reaction can cause lung damage and eventual death in COVID-19 victims.

The study model showed CBD down-regulated the cytokines, which helped improve oxygen levels and supported recovery of damaged lung tissues. The researchers also intend to perform similar studies to understand how CBD might help other organs recover from the effects of the virus. Researchers from University of Nebraska and the Texas Biomedical Research Institute also took part. In apeer-reviewed article in Brain, Behaviour, and Immunity, the authors said further research is needed to understand if CBD can help patients infected by the virus.

Now early results from an ongoing Israeli study is adding to the growing evidence that cannabis ingredients could be a game changing treatment in the fight against COVID-19. The new terpene study is being performed by two Israeli research and development companies,Eybnawhich specializes in terpene based medicines, and CannaSoul Analytics. The study looks at a proprietary terpene formulation called NT-VRL, which was created by Eybna to treat inflammatory conditions such as the cytokine storm syndrome found in COVID-19 patients. The formulation contains 30 individual terpenes that are potential anti-inammatory agents all working together to create a positive impact.

While results are ongoing and are yet to be completed, peer reviewed or published, these are positive steps that warrants further investigation into the application of CBD.

This is far from the only investigation into CBD medical benefits.

Researchers at the University of Lethbridge in Alberta,Canada, revealed at the beginning of July that certain kinds of high CBD strains could help treat people infected with the virus or even prevent it from developing in the first place by managing to reduce virus receptors.

Study authors found extract from high CBD strains could help to regulate an enzyme that coronavirus attaches to thereby blocking the viruss ability to infect cells. Results were published on peer review website Preprints.

In Israel, there are several companies and trials underway on how CBD can be used to battle COVID-19. One such example is the partnership of InnoCan Pharma and Tel Aviv University who are working on a new treatment for COVID-19 using exosomes loaded with CBD. Exosomes are small particles created when stem cells multiply. The method will utilise the exosomes as homing missiles, as they can uniquely target cell organs that have been damaged.

As it stands, CBD is still an area under development for the treatment of COVID-19. While there have been some promising results on CBDs anti-inflammatory properties, more studies are needed before leading into clinical trials to test effectiveness. This can take anywhere from months to years.

Speed, agility, and innovation are required from governments, businesses, and society in crafting responses to cope with this evolving new normal. In this period of uncertainty, every therapeutic opportunity and avenue must be considered. CBD opens the door to various exciting possibilities.

Read the rest here:
COVID is shifting the conversation about the medical application of CBD - Open Access Government

Remarkable Growth in the Artificial Embryo Market by top key players like MERLN Institute of Maastricht University, University of Cambridge,…

A2Z Market Research announces the release of the Artificial Embryo Market research report. The market is predicted to grow at a healthy pace in the coming years. Artificial Embryo Market 2020 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. The Market report offers remarkable data regarding the industrys growth parameters, the current state of the market in terms of analysis of possible economic situations, and macroeconomic analysis.

An artificial embryo is an embryo prepared by the use of various technologies in artificial conditions with the help of stem cells. These cells are grown in culture media which provides the required nutrition for the growth. increase in stem cell banking and various other advanced technologies are expected to promote the growth of the Artificial Embryo Market.

The artificial Embryo Market is growing at a CAGR of +10% during the forecast period 2020-2026.

Sample Report with Latest Industry Trends @:

https://www.a2zmarketresearch.com/sample?reportId=313209

The top companies in this report include:

MERLN Institute of Maastricht University, University of Cambridge, University of Michigan, Rockefeller University, MRC London Institute of Medical Sciences

This report provides an in-depth review of the current state of the Artificial Embryo market, daring its growth and all other essential elements in all of the major markets of the county.It presents a gigantic amount of market data, compiled using myriad primary and secondary research practices.The data in this report has been reduced on a business basis using various systematic methods.

For a comprehensive analysis, the Artificial Embryo market is segmented by product type, region, and application.Due to its regional focus, the market is alien to North America, Europe, Asia-Pacific, the Middle East and Africa as well as Latin America.Major companies are working on distributing their products and services across different regions.In addition, procurements and associations from some of the leading organizations.All of the factors intended to drive the global marketplace are examined in depth.

Get Impressive [emailprotected]:

https://www.a2zmarketresearch.com/discount?reportId=313209

This report gives an in-depth and broad understanding of the Artificial Embryo Market. With exact data cover all key features of the current market, this report offers widespread data on leading companies. Appreciative of the market state by amenability of correct historical data regarding each and every sector for the forecast period is mentioned. Driving forces, restraints, and opportunities are given to help give an improved picture of this market investment for the forecast period of 2020 to 2026.

Key Factors Impacting Market Growth:

o Convergence of data with accuracy and high speed o Rising demand for efficient computing o Increasing opportunities through improved research, computation, and data analysis performances o High price and data security issues

The main questions answered in the report are:

Reasons to Purchase this Report:

* Estimates 2020-2026 Artificial Embryo Market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=313209

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Excerpt from:
Remarkable Growth in the Artificial Embryo Market by top key players like MERLN Institute of Maastricht University, University of Cambridge,...

Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate…

Key Developments in the Market:

In March 2018, Kaneka Corporation announced that they have acquired a patent in the Japan for the creation of the method to mass-culture pluripotent stem cells including iPS cells and ES cells. This will help the company to use the technology to produce high quality pluripotent stem cells which can be used in the drug and cell therapy.

In March 2015, Fujifilm announced that they have acquired Cellular Dynamics International. The main aim of the acquisition is to expand their business in the iPS cell-based drug discovery support service with the use of CDS technology. It will help them to product high- quality automatic human cells with the help of the induced pluripotent stem cells. This will help the company to be more competitive in the drug discovery and regenerative medicine.

Now Get 20% Discount on This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-stem-cells-market

Global Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

Induced pluripotent stem cells (iPSCs) market is segmented of the basis of derived cell type, application and end- user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Global Induced Pluripotent Stem Cells (iPSCs) Market Drivers:

Increasing R&D investment activities is expected to create new opportunity for the market.

Increasing demand for personalized regenerative cell therapies among medical researchers & healthcare is expected to enhance the market growth. Some of the other factors such as increasing cases of chronic diseases, growing awareness among patient, rising funding by government & private sectors and rising number ofclinical trialsis expected to drive the induced pluripotent stem cells (iPSCs) market in the forecast period of 2020 to 2027.

High cost of the induced pluripotent stem cells (iPSCs) and increasing ethical issues & lengthy processes is expected to hamper the market growth in the mentioned forecast period.

Access Full report @https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:Corporatesales@databridgemarketresearch.com

Read the original post:
Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate...